Immunomedics

$85.34
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.02 (-0.02%) Today
$0.00 (0.00%) As of 7:05 AM EDT after-hours

Why Robinhood?

You can buy or sell Immunomedics and other stocks, options, ETFs, and crypto commission-free!

About IMMU

Immunomedics, Inc. researching, developing, manufacturing, and marketing biopharmaceutical products. It focuses on monoclonal antibody-based products for the targeted treatment of cancer. Read More The company was founded by David M. Goldenberg in July 1982 and is headquartered in Morris Plains, NJ.

Employees
366
Headquarters
Morris Plains, New Jersey
Founded
1982
Market Cap
19.73B
Price-Earnings Ratio
Dividend Yield
Average Volume
12.76M
High Today
$86.00
Low Today
$85.10
Open Price
$85.29
Volume
6.81M
52 Week High
$86.91
52 Week Low
$8.80

Collections

IMMU News

ReutersSep 15

Tech, healthcare mega deals boost virus-stricken M&A market

(Reuters) - After adapting to working from home in the COVID-19 pandemic, cash-rich technology and healthcare companies have now mastered dealmaking from home.
BloombergSep 14

Dealmakers See $69 Billion of M&A in Year’s Busiest Weekend

(Bloomberg) -- A blockbuster Sunday of takeovers has bled into Monday for the fastest start to a week for global dealmaking this year. Companies led by Japanes
BenzingaSep 14

Gilead Analysts Dissect Immunomedics Deal: 'Pricier But Bold Move Into Oncology'

Gilead Sciences, Inc. (NASDAQ: GILD) announced over the weekend a deal to buy Immunomedics, Inc. (NASDAQ: IMMU), which recently transitioned to a commercial-sta

IMMU Earnings

-$0.73
-$0.49
-$0.24
$0.00
Q2 2019
Q3 2019
Q4 2019
Q1 2020
Q2 2020
Q3 2020
Q4 2020
Q1 2021
Estimated
per share
Actual
Expected Oct 28, After Hours

You May Also Like

More IMMU News

BloombergSep 14

Gilead Ramps Up Cancer Focus With $21 Billion Immunomedics Deal

(Bloomberg) -- Gilead Sciences Inc. agreed to acquire Immunomedics Inc. for about $21 billion, a substantial premium for the maker of a promising breast-cancer
ReutersSep 14

Gilead bolsters cancer portfolio with $21 billion acquisition of Immunomedics

(Reuters) - Gilead Sciences Inc will acquire biotech company Immunomedics Inc for $21 billion, a move that will strengthen its cancer portfolio by gaining acces
BenzingaSep 14

Gilead To Explore Trodelvy Drug Against Different Cancers After $21B Merger With Immunomedics

After initial reports emerged on Saturday about a potential acquisition deal, Gilead Sciences Inc (NASDAQ: GILD) confirmed that it's set to purchase Immunomedic
ReutersSep 13

Gilead to buy cancer drugmaker Immunomedics for $21 billion

FILE PHOTO: Gilead Sciences Inc pharmaceutical company is seen during the outbreak of the coronavirus disease (COVID-19), in California (Reuters) - Gilead Scie
MarketWatchSep 13

Gilead reaches $21 billion deal for Immunomedics

Gilead Sciences Inc. will pay $21 billion to buy biotech Immunomedics Inc. and its prized breast-cancer drug, the company said Sunday, a sign of the value of th
ReutersSep 13

Gilead to buy Immunomedics in a $21 bln deal

Sept 13 (Reuters) - Gilead Sciences Inc will acquire biopharmaceutical company Immunomedics Inc for $21 billion in a deal that would further expand Gilead's por
BenzingaSep 12

Report: Gilead Sciences And Cancer Treatment Company Immunomedics In $20B Deal

Gilead Sciences Inc. (NASDAQ: GILD) is gearing up to purchase drug innovator Immunomedics Inc. (NASDAQ: IMMU) for a price tag exceeding $20 billion. Per the Wa
Robinhood Snacks newsletters and podcasts reflect the opinions of only the authors who are associated persons of Robinhood Financial LLC and do not reflect the views of Robinhood Markets, Inc. or any of its subsidiaries or affiliates. They are meant for informational purposes only, are not intended to serve as a recommendation to buy or sell any security in a self-directed Robinhood account or any other account, and are not an offer or sale of a security. They are also not research reports and are not intended to serve as the basis for any investment decision. Any third-party information provided therein does not reflect the views of Robinhood Markets, Inc., Robinhood Financial LLC, or any of their subsidiaries or affiliates. All investments involve risk and the past performance of a security or financial product does not guarantee future results or returns. Keep in mind that while diversification may help spread risk, it does not assure a profit or protect against loss. There is always the potential of losing money when you invest in securities or other financial products. Investors should consider their investment objectives and risks carefully before investing. The price of a given security may increase or decrease based on market conditions and customers may lose money, including their original investment. Robinhood Financial LLC, member FINRA/SIPC.

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.